Amgen drug fails to improve survival in multiple myeloma trial
August 13, 2014 at 16:55 PM EDT
Aug 13 (Reuters) - A Phase 3 trial of Amgen Inc's Kyprolis drug failed to show it could extend survival compared to standard care for patients with advanced multiple myeloma, a type of blood cancer that develops in the bone marrow.
